CN117815223A - Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma - Google Patents
Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma Download PDFInfo
- Publication number
- CN117815223A CN117815223A CN202410252314.4A CN202410252314A CN117815223A CN 117815223 A CN117815223 A CN 117815223A CN 202410252314 A CN202410252314 A CN 202410252314A CN 117815223 A CN117815223 A CN 117815223A
- Authority
- CN
- China
- Prior art keywords
- esophageal squamous
- ginkgo
- squamous carcinoma
- pharmaceutically acceptable
- ginkgetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010041823 squamous cell carcinoma Diseases 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 235000008100 Ginkgo biloba Nutrition 0.000 title abstract description 49
- 241000218628 Ginkgo Species 0.000 title abstract description 47
- 235000011201 Ginkgo Nutrition 0.000 title abstract description 47
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 title abstract description 24
- 230000006907 apoptotic process Effects 0.000 claims abstract description 11
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 claims description 22
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 claims description 21
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 6
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 6
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000007933 dermal patch Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000004709 cell invasion Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 230000009545 invasion Effects 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000006698 induction Effects 0.000 abstract description 5
- 230000009036 growth inhibition Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 54
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 229930003935 flavonoid Natural products 0.000 description 12
- 235000017173 flavonoids Nutrition 0.000 description 12
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- -1 flavonoid compound Chemical class 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- VGGSULWDCMWZPO-ODEMIOGVSA-N spinosin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=2C(=O)C=C(OC=2C=C1OC)C=1C=CC(O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VGGSULWDCMWZPO-ODEMIOGVSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 229920002982 Procyanidin A2 Polymers 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- VGGSULWDCMWZPO-UHFFFAOYSA-N flavoayamenin Natural products COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O VGGSULWDCMWZPO-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 2
- 235000008466 glycitein Nutrition 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- MMDUKUSNQNWVET-WMRYYKKOSA-N 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1C1=C(O)C([C@H]2[C@@H]([C@@H](O)[C@@H](O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MMDUKUSNQNWVET-WMRYYKKOSA-N 0.000 description 1
- 102000007347 Apyrase Human genes 0.000 description 1
- 108010007730 Apyrase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- PEFASEPMJYRQBW-HKWQTAEVSA-N Robinin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-HKWQTAEVSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 description 1
- BGLPQQKZNUKSAR-UHFFFAOYSA-N isorhamnetin-3-O-rutinoside Natural products COc1ccc(cc1O)C2=C(OC3OC(COCC4OC(O)C(O)C(O)C4O)C(O)C(O)C3O)C(=O)c5c(O)cc(O)cc5O2 BGLPQQKZNUKSAR-UHFFFAOYSA-N 0.000 description 1
- DDELFAUOHDSZJL-UHFFFAOYSA-N kaempferol 3-O-rutinoside-7-O-rhamnoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C1=O DDELFAUOHDSZJL-UHFFFAOYSA-N 0.000 description 1
- PEFASEPMJYRQBW-UHFFFAOYSA-N kaempferol 7-O-alpha-L-rhamnopyradoside 3-O-beta-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(OC4C(C(O)C(O)C(C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- PEFASEPMJYRQBW-XMWKPCQISA-N robinin Natural products O(C[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O4)c3)C2=O)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PEFASEPMJYRQBW-XMWKPCQISA-N 0.000 description 1
- NIABBGMPPWXWOJ-UHFFFAOYSA-N schaftoside Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C(OC2C(C(O)C(O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O NIABBGMPPWXWOJ-UHFFFAOYSA-N 0.000 description 1
- MMDUKUSNQNWVET-UHFFFAOYSA-N schaftozide Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C(C(O)C(O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MMDUKUSNQNWVET-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
The invention provides an application of ginkgo biflavone in preparing an anti-esophageal squamous carcinoma drug. Experimental results show that the ginkgo biflava has remarkable growth inhibition, invasion inhibition and apoptosis induction effects on esophageal squamous carcinoma cell lines KYSE410, KYSE150, KYSE450 and KYSE510, and the ginkgo biflava can be used for preparing medicines for preventing and treating esophageal squamous carcinoma.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of ginkgetin in preparation of medicines for resisting esophageal squamous cell carcinoma.
Background
Esophageal cancer is a malignant tumor which seriously endangers the health of people worldwide, and China is a country with higher incidence rate and mortality rate of esophageal cancer. Esophageal cancer is largely divided into two histological types, esophageal squamous carcinoma (ESCC) and Esophageal Adenocarcinoma (EAC). In China, most of esophageal cancers are ESCC, and the survival rate of 5 years is lower than 15%. ESCC is extremely prone to malignant progression and metastasis, more than half of ESCC patients cannot undergo surgical excision or have metastasized at the time of initial diagnosis, and the 5-year survival rate of patients with metastasized advanced ESCC is less than 5%. With the progress of diagnosis and treatment level, the survival rate of malignant tumor patients in 5 years is obviously improved, but the death rate of metastatic tumor patients is still extremely high, and compared with the prior art, the death rate is not obviously improved, and the main reason is that the comprehensive cognition of the tumorigenesis development mechanism is lacking at present. The first-line medicine for clinically treating esophageal squamous carcinoma is a platinum compound, but is extremely easy to generate drug resistance, and tumor recurrence easily occurs after treatment.
Currently, there is no clear standard regimen for pre-operative chemotherapy of esophageal squamous carcinoma. Platinum, paclitaxel, fluorouracil, immunotherapy, and the like are mostly used in most clinical studies. Although these therapies work in combination to achieve a certain effect, patient tolerance is still acceptable and there is no increase in intraoperative complications. However, due to the effects of the dose of the chemotherapeutic agent, the chemotherapy cycle, and the time span of surgery after chemotherapy, the effects of the combination of these chemotherapeutic agents on the survival and survival status of the patient cannot be accurately determined. The use of these esophageal squamous carcinoma therapies remains to be further studied and elucidated.
The flavonoid compound is a polyphenol compound widely existing in the nature, has the biological effects of resisting oxidization and inflammation, and has low toxic effect. Can be used for treating cardiovascular and cerebrovascular diseases, hypertension, atherosclerosis and autoimmune diseases. The biflavanoid compound is a compound formed by condensing two molecules of flavone or derivatives thereof. The biflavanoid compound has a plurality of condensation modes, can be condensed through carbon-carbon bonds, can also be condensed through ether oxygen bonds, and has different condensation positions.
Ginkgo biflavone (Ginkgetin) is a flavonoid compound from ginkgo with anti-inflammatory and antioxidant biological effects:
ginkgo biflavone has application in various cardiovascular and cerebrovascular diseases. The anti-tumor effect of ginkgo biflava is reported to be less, and the effect of ginkgo biflava in the malignant progress of esophageal squamous carcinoma is not reported yet.
Disclosure of Invention
The invention discovers that the biflavone compound has very remarkable effect in the treatment of esophageal squamous carcinoma, and can block malignant progress of esophageal squamous carcinoma cells in the aspects of apoptosis induction, growth, invasion inhibition and the like.
Therefore, the invention provides application of ginkgo biflavone or pharmaceutically acceptable salt thereof in preparing medicines for resisting esophageal squamous cell carcinoma.
In one embodiment, the medicament comprises ginkgetin or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.
In another aspect, the invention provides a pharmaceutical composition for treating esophageal squamous carcinoma, which comprises ginkgetin or pharmaceutically acceptable salt thereof and pharmaceutically acceptable auxiliary agents.
In the invention, the anti-esophageal squamous carcinoma comprises at least one of inhibiting the growth of esophageal squamous carcinoma cells, inhibiting the invasion of esophageal squamous carcinoma cells and inducing the apoptosis of esophageal squamous carcinoma cells.
In the present invention, the pharmaceutically acceptable salts include salts of ginkgetin with pharmaceutically acceptable acids or bases, and particularly salts of pharmaceutically acceptable inorganic or organic acids may be mentioned.
The medicaments and pharmaceutical compositions of the invention are suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) or pulmonary administration.
The medicaments/pharmaceutical compositions of the invention suitable for oral administration may for example be presented in discrete units, e.g. capsules, tablets, each containing a predetermined amount of the active ingredient. Or as a supplement in an oil-in-water liquid emulsion, a water-in-oil liquid emulsion, or an aqueous solution. The active ingredient may also be presented as a pill, suppository or paste. The medicaments/pharmaceutical compositions according to the invention suitable for topical administration may be formulated, for example, as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. Alternatively, the formulation may comprise a patch or dressing, such as a bandage or plaster, to which the active ingredient is applied, and optionally one or more excipients or diluents. The pharmaceutical/pharmaceutical compositions of the present invention suitable for topical application to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, particularly a sterile aqueous solvent for the agent. The medicament/pharmaceutical composition of the invention for rectal administration may be provided in the form of suppositories. The medicaments/pharmaceutical compositions of the invention suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active compound such carriers as are known in the art to be appropriate. The pharmaceutical/pharmaceutical compositions of the present invention suitable for nasal administration include meal powders having, for example, a particle size in the range of about 20 to about 500 microns. The pharmaceutical/pharmaceutical compositions of the present invention suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain preservatives, buffers, bacteriostats and solutes, which render the formulation isotonic with the blood of the patient. Aqueous and non-aqueous sterile suspensions may include suspending and thickening agents, as well as liposome or other microparticle systems, which aim to target the compound to a blood component or organ or organs.
It will be appreciated that the pharmaceutical/pharmaceutical compositions of the present invention may include other agents conventional in the art regarding the type of formulation in question, in addition to the ingredients specifically mentioned above. For example, formulations suitable for oral administration may include other agents such as sweetening agents, thickening agents and flavouring agents.
Various delivery systems are known and may be used to administer the therapeutic agents of the present invention, e.g., encapsulated in liposomes, microparticles, microcapsules, and the like. Delivery methods include, but are not limited to, intra-arterial, intramuscular, intravenous, intranasal, and oral routes. In a specific embodiment, the drug/pharmaceutical composition of the invention may be topically applied to an area in need of treatment. Such local administration may be achieved, for example, by local infusion during surgery, by injection or by catheter.
Thus, the drug/pharmaceutical composition of the present invention may be one of tablets, powders, granules, pills, capsules, solutions, eye drops, emulsions, suspensions, ointments, oils, pastes, foams, sprays, injections, skin patches, suppositories, liposome preparations, microparticle preparations, microcapsule preparations.
In the drug/pharmaceutical composition according to the present invention, the ginkgo biflavone or a pharmaceutically acceptable salt thereof may be present in an amount of 0.01% to 50%, preferably 0.1% to 10%, more preferably 0.5% to 5%, most preferably 1% to 2% of the total weight.
The amount of treatment can be determined empirically and will vary with the pathology being treated, the weight of the subject being treated, and the efficacy and toxicity of the agent. Similarly, one skilled in the art can readily determine suitable dosage formulations and methods of administering the agents. For example, for adult patients, the ginkgo biflavones or pharmaceutically acceptable salts thereof of the present invention can be orally or parenterally administered as an administration amount of 0.001mg to 500mg for 1 day, 1 time or divided into several times for 1 day.
Advantageous effects
The invention provides application of ginkgo biflavone in preparing an anti-esophageal squamous carcinoma drug. Experimental results show that ginkgo biflava has remarkable apoptosis induction effect on esophageal squamous carcinoma cell lines KYSE410, KYSE150, KYSE450 and KYSE510, and can remarkably induce activation of apoptosis related proteins caspase 3 and PARP. The ginkgo biflava is capable of dose-dependently inhibiting the growth of the esophageal squamous carcinoma cell lines KYSE410, KYSE150, KYSE450 and KYSE510 as assessed by MTS method. The ginkgetin can inhibit the invasion of esophageal squamous carcinoma cell lines KYSE410, KYSE150, KYSE450 and KYSE510 in a dose-dependent manner by evaluating through a Transwell method. In KYSE450 and KYSE510 tumor-bearing mouse models, ginkgetin can effectively inhibit the increase of tumor volume and has good anticancer effect. Therefore, the ginkgo biflava can be used for preparing medicines for preventing and treating esophageal squamous cell carcinoma.
Drawings
FIG. 1 is a graph showing the results of the growth inhibitory effect of ginkgo biflavone of example 1 on esophageal squamous carcinoma cell lines. Wherein,P<0.05，/>P<0.01，/>P<0.001，/>P<0.0001 vs control (ginkgetin 0. Mu.M).
FIG. 2 is a graph showing the results of the invasion inhibition effect of ginkgo biflavone of example 2 on esophageal squamous carcinoma cell lines. Wherein,P<0.05，/>P<0.01，/>P<0.001 vs control group (ginkgetin 0. Mu.M); cont means that ginkgo biflavone is 0 mu M.
FIG. 3 is a graph showing the results of apoptosis induction of esophageal squamous carcinoma cell lines by ginkgo biflava of example 3. Wherein cont represents 0 μm of ginkgetin.
FIG. 4 is a schematic diagram showing the results of the induction of apoptosis key proteins of esophageal squamous carcinoma cell line by ginkgo biflava of example 4. Wherein,P<0.01，/>P<0.001 vs cont (ginkgo biflavone 0. Mu.M).
FIG. 5 is a graph showing the anti-tumor effect of ginkgo biflava of example 5 on tumor-bearing mice of esophageal squamous carcinoma cell lines KYSE450 and KYSE 510. Wherein,P<0.001 vs cont (ginkgo biflavone 0. Mu.M).
FIG. 6 is a graph showing the comparison of the antitumor effects of ginkgo biflavone and other flavonoid compounds of example 6. Wherein cont represents the administration amount of 0. Mu.M.
FIG. 7 is a comparative schematic of the ginkgo biflavone anti-esophageal squamous carcinoma and other types of tumors of example 7. Wherein cont represents 0 μm of ginkgetin
Detailed Description
Hereinafter, preferred examples of the invention will be described in detail. The examples are presented for better presentation of the invention and are not intended to be limiting. Insubstantial modifications and adaptations of the embodiments in accordance with the summary of the invention remain within the scope of the invention.
The experimental methods in the following examples are conventional methods unless otherwise specified. The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications.
Example 1: growth inhibition effect of ginkgo biflavone on esophageal squamous carcinoma cell line
1. Cell culture
Human esophageal squamous carcinoma cell lines KYSE410, KYSE150, KYSE450 and KYSE510 were cultured in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin streptomycin. The incubator temperature was 37℃and contained 5% CO 2 。
2. Cell growth ability assay
KYSE410, KYSE150, KYSE450 and KYSE510 cell lines were used in 3X 10 3 Density of individual/wells was seeded in 96-well plates and after cell attachment, different concentrations of ginkgetin (1, 2.5, 5, 10, 25, 50 μm) were added. After 72 hours, a 10% MTS solution was prepared in RPMI 1640 medium, the cultured cells were removed, the upper medium was discarded, the prepared MTS was added for incubation for 2 hours, and absorbance was measured under conditions of a microplate reader 490 nm.
Referring to fig. 1, the results show that ginkgo biflava is capable of inhibiting the growth of various esophageal squamous carcinoma cell lines in a dose-dependent manner.
Example 2: invasion inhibition effect of ginkgo biflavone on esophageal squamous carcinoma cell line
1. Cell invasiveness detection
KYSE410, KYSE150, KYSE450 and KYSE510 cell lines were cultured in serum free medium for 24 hours. Penetration using an 8 μm pore sizeAnd a chamber cell, wherein 100 mu L of matrigel is added into an upper chamber of the cell, and the matrigel is solidified after incubation for 1 hour at 37 ℃. The prepared KYSE410, KYSE150, KYSE450 and KYSE510 cell lines were used for 1×10 5 The density of each well was inoculated into the upper chamber of the puncture chamber, the lower chamber was filled with 1. 1 mL RPMI 1640 medium containing 20% fetal bovine serum, and with different concentrations of ginkgo biloba biflava (2.5, 5, 10, 25. Mu.M), and the puncture chamber was placed in an incubator for incubation for 24 hours. After removal, the inner wall of the upper chamber was wiped clean with a cotton swab, and the upper chamber was stained with a 2% crystal violet solution for 30 minutes. After the dyeing is finished, the floating color is slowly washed by flowing water, the upper chamber is dried, and the total number of cells passing through the upper chamber is counted by photographing.
Referring to fig. 2, the results show that ginkgo biflava is capable of inhibiting the invasion of various esophageal squamous carcinoma cell lines in a dose-dependent manner.
Example 3: apoptosis induction effect of ginkgo biflavone on esophageal squamous carcinoma cell line
1. Observation of apoptosis morphology
KYSE410, KYSE150, KYSE450 and KYSE510 cell lines were inoculated in RPMI 1640 medium containing 10% foetal calf serum. After cell attachment, ginkgo biflavones (2.5, 5, 10, 25. Mu.M) were added at different concentrations. After 24 hours of incubation, changes in cell morphology were observed by microscopy.
Referring to fig. 3, the results show that ginkgo biflavones can destroy cell integrity and reduce cell volume in a dose-dependent manner, and become compact spherical bodies, namely, form apoptotic bodies.
Example 4: induction of apoptosis key protein of esophageal squamous carcinoma cell line by ginkgo biflava
KYSE410, KYSE150, KYSE450 and KYSE510 cell lines were inoculated in RPMI 1640 medium containing 10% foetal calf serum. After cell attachment, ginkgo biflavones (2.5, 5, 10, 25. Mu.M) were added at different concentrations. After 24 hours incubation, cells were collected along with supernatant, and after centrifugation at 12000 rpm for 10 minutes at 4℃the pellet was collected. RIPA lysate was added and lysed on ice for 1 hour, during which time shaking was performed every 10 minutes. After completion of the cleavage, the supernatant was collected after centrifugation at 12000 rpm at 4℃for 20 minutes to obtain a protein lysate. The sheared Poly (apyrase) ribose polymerase (Poly ADP-ribose polymerase, PARP) was further visualized by an Enzyme-linked immunosorbent assay (Enzyme-linked immunosorbnent assay, ELISA) method at high throughput. PARP is a cleavage substrate for caspases, a core member of apoptosis, and plays a key role in apoptosis. Increased shear of PARP means that the cells appear to undergo significant apoptosis. Protein lysate samples (100. Mu.L/well) were sequentially added to a proprietary shear type PARP ELISA 96 well plate and incubated at 37℃for 2.5 hours after sealing. After the incubation is completed, the sample is discarded, and the sample is cleaned for 4 times by using a cleaning liquid and discarded. Shear type PARP antibodies were added to 96-well plates (100. Mu.L/well), incubated for 1 hour at room temperature with shaking, washed 4 times with washing solution, and discarded. After adding a reaction substrate to each hole and incubating for 30 minutes at room temperature in a dark place, adding a reaction stopping solution, and measuring the absorbance value under the condition of a microplate reader 450 and nm.
Referring to fig. 4, the results show that ginkgo biflavone dose-dependently induces up-regulation of the expression of sheared PARP in multiple esophageal squamous carcinoma cell lines.
Example 5: antitumor effect of ginkgetin on esophageal squamous carcinoma cell lines KYSE450 and KYSE510 tumor-bearing mice
Will be 2.5X10 6 KYSE450 or KYSE510 cells were injected subcutaneously into the upper limb of nude mice until the tumor had grown to about 100 mm 3 After left and right, KYSE450 or KYSE510 tumor bearing mice were randomly divided into two groups, a control group and a ginkgetin group. Ginkgo Biflavone (15 mg/kg) groups were administered by intragastric administration once daily for a total of 3 weeks. The control group was administered with the same dose of physiological saline by daily gavage for 3 weeks. Tumor volumes were measured once a week. The tumor volume calculation formula is: volume = tumor long diameter x tumor transverse diameter 2 x 0.5. Tumor tissues were collected on day 28, paraffin-embedded, fixed, and sectioned to prepare paraffin-embedded sections, and expression of proliferation-critical Protein (PCNA) and apoptosis-critical protein (sheared PARP) in KYSE450 and KYSE510 tissues was observed through immunohistochemical experiments.
Referring to fig. 5, the results show that ginkgo biflava significantly inhibits the growth of KYSE450 and KYSE510 tumors in a xenogenic tumor-bearing mouse model. Ginkgetin significantly inhibits PCNA expression in KYSE450 and KYSE510 tumors; significantly up-regulates the expression of sheared PARP in KYSE450 and KYSE510 tumor tissues.
Example 6: the ginkgetin can inhibit the growth of esophageal squamous carcinoma cell line more effectively than other flavonoid compounds
1. Cell culture
The human esophageal squamous carcinoma cell line KYSE450 was cultured in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin streptomycin. The incubator temperature was 37℃and contained 5% CO 2 。
2. Cell growth ability assay
KYSE450 cell line was used at 3X 10 3 The density of the individual/well is inoculated into a 96-well plate, and after the cells are attached, different flavonoids (total of 8 flavonoids are added, each flavonoid dose is 5 mu M) including ginkgetin, procyanidin A2 (Procyanidin A2), glycitein (Glycitein), narcissin, schaftoside, robinin, firework glycoside (Nicotiforin) and Spinosin (Spinosin) are added. After 72 hours, a 10% MTS solution was prepared in RPMI 1640 medium, the cultured cells were removed, the upper medium was discarded, the prepared MTS was added for incubation for 2 hours, and absorbance was measured under conditions of a microplate reader 490 nm.
Referring to fig. 6, the results show that ginkgo biflava can inhibit the growth of esophageal squamous carcinoma cell lines more effectively than other flavonoid compounds.
Example 7: the ginkgetin can obtain more effective tumor growth inhibition effect on esophageal squamous carcinoma cells than other types of tumor cells
1. Cell culture
Human esophageal squamous carcinoma cell line KYSE450, human small-cell lung carcinoma cell line H446, human breast carcinoma cell line MDA231, human glioma cell line U87 and human gastric carcinoma cell line MGC803 are cultured in RPMI 1640 medium containing 10% of fetal bovine serum and 1% of penicillin streptomycin. The incubator temperature was 37℃and contained 5% CO 2 。
2. Cell growth ability assay
KYSE450, H446, MDA231, U87 and MGC803 cell lines were seeded at a density of 3X 103 cells/well in 96-well plates, and after cell attachment, ginkgo biloba biflavone (5. Mu.M) was added. After 72 hours, a 10% MTS solution was prepared in RPMI 1640 medium, the cultured cells were removed, the upper medium was discarded, the prepared MTS was added for incubation for 2 hours, and absorbance was measured under conditions of a microplate reader 490 nm.
Referring to fig. 7, the results show that ginkgo biflava can achieve more effective tumor growth inhibition in esophageal squamous carcinoma cells than in other types of tumor cells.
Example 8:
the ginkgo biflava is wrapped in liposome to prepare liposome ginkgo biflava as a medicament for treating esophageal squamous cell carcinoma.
Example 9:
mixing ginkgo biflavone and other flavonoid medicines according to a ratio (mass ratio=1:1), adding excipient according to a ratio required by a preparation, and preparing into tablets.
Example 10:
mixing ginkgo biflavone and other flavonoid medicines according to a ratio (mass ratio=1:1), adding an excipient according to a ratio required by a preparation, and preparing into powder.
Example 11:
mixing ginkgo biflava with other flavonoid medicines according to a proportion (mass ratio=1:1), performing spray granulation, drying, and granulating to obtain granules, wherein the granules are used as medicines for preventing and treating esophageal squamous cell carcinoma.
Example 12:
mixing ginkgo biflavone and other flavonoid medicines in a ratio (mass ratio=1:1), dissolving with water, fine filtering, packaging, sterilizing and preparing into injection.
Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, although the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (7)
1. Application of ginkgetin or pharmaceutically acceptable salt thereof in preparing medicine for resisting esophageal squamous cell carcinoma is provided.
2. The use according to claim 1, wherein the medicament comprises ginkgetin or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.
3. The use of claim 1, wherein the anti-esophageal squamous carcinoma comprises at least one of inhibiting esophageal squamous carcinoma cell growth, inhibiting esophageal squamous carcinoma cell invasion, and inducing esophageal squamous carcinoma cell apoptosis.
4. The use according to claim 1, wherein the pharmaceutically acceptable salt comprises a salt of ginkgetin with a pharmaceutically acceptable acid or base.
5. The use according to claim 1, wherein the medicament is suitable for oral, rectal, nasal, topical, vaginal, parenteral or pulmonary administration.
6. The use according to claim 1, wherein the medicament is one of a tablet, powder, granule, pill, capsule, solution, eye drop, emulsion, suspension, ointment, oil, paste, foam, spray, injection, skin patch, suppository, liposomal formulation, microparticle formulation, microcapsule formulation.
7. The use according to claim 1, wherein in the medicament the amount of ginkgetin or a pharmaceutically acceptable salt thereof is between 0.01% and 50% by total weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410252314.4A CN117815223A (en) | 2024-03-06 | 2024-03-06 | Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410252314.4A CN117815223A (en) | 2024-03-06 | 2024-03-06 | Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117815223A true CN117815223A (en) | 2024-04-05 |
Family
ID=90506298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410252314.4A Pending CN117815223A (en) | 2024-03-06 | 2024-03-06 | Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117815223A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020291A2 (en) * | 1997-10-23 | 1999-04-29 | Pharmaprint, Inc. | Pharmaceutical grade ginkgo biloba |
| CN103214445A (en) * | 2013-05-08 | 2013-07-24 | 郑州大学 | Preparation method and use of quercetin amide derivative |
| CN103239437A (en) * | 2013-05-08 | 2013-08-14 | 郑州大学 | Application of quercetin derivative in preparation of antitumor medicine |
| CN105998697A (en) * | 2016-06-30 | 2016-10-12 | 济南星懿医药技术有限公司 | Medicine composition for treating esophagus cancer |
-
2024
- 2024-03-06 CN CN202410252314.4A patent/CN117815223A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020291A2 (en) * | 1997-10-23 | 1999-04-29 | Pharmaprint, Inc. | Pharmaceutical grade ginkgo biloba |
| CN103214445A (en) * | 2013-05-08 | 2013-07-24 | 郑州大学 | Preparation method and use of quercetin amide derivative |
| CN103239437A (en) * | 2013-05-08 | 2013-08-14 | 郑州大学 | Application of quercetin derivative in preparation of antitumor medicine |
| CN105998697A (en) * | 2016-06-30 | 2016-10-12 | 济南星懿医药技术有限公司 | Medicine composition for treating esophagus cancer |
Non-Patent Citations (4)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation | |
| JP3007627B2 (en) | Use of the natural chemical substance arsenic hexaoxide as a novel antitumor therapeutic and its pharmaceutical composition | |
| CN1383381A (en) | Therpauetic agent of osteoporisis comprising active ingredient of quercetin derivatives | |
| WO2000050053A1 (en) | Natural product composition for use in treating cancer | |
| KR20190124668A (en) | Composition for treating and preventing of metastatic ovarian cancer, endometrial cancer, or breast cancer | |
| CN102552908B (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
| WO2005003145A1 (en) | Shanzhuyu extract and uses thereof | |
| JP6837960B2 (en) | Compositions containing melatonin and flavonoids for use in the treatment of chemotherapy-resistant tumors | |
| CN113143913A (en) | Application of eudesmane type sesquiterpene compound in preparation of anti-pancreatic cancer drugs | |
| CN117815223A (en) | Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma | |
| US20080176932A1 (en) | Pharmaceutical Compositions Containing Baicalein And Baicalin With Synergistic Effect In Tumor Treatment | |
| TW202002987A (en) | Use of ginsenoside M1 for treating oral cancer | |
| JP5086805B2 (en) | "Preparation of purified anti-cancer ginseng extract and its cancer fusion preparation" | |
| CN101785807A (en) | Application of traditional Chinese medicine compound Zuojin prescription in preparing medicine for treating gastric cancer | |
| TWI736173B (en) | Mycelium of liquid culture of antrodia camphorata extract, compounds of mycelium of liquid culture of antrodia camphorata extract, and use thereof for treating ischemic stroke | |
| CN112439067B (en) | Application of SGLT2 inhibitor in preparation of product for improving sensitivity of antitumor drugs | |
| CN110876745A (en) | Resveratrol and procyanidin composition with high anticancer activity | |
| CN112218620A (en) | Treatment of cancer by guanidine salt derivatives | |
| KR100519456B1 (en) | Composition for Suppressing the toxicity of anti-cancer treatment | |
| CN104887690B (en) | Application of the chonglou saponin in antitumor drug is prepared | |
| Wang et al. | Experimental study of realgar on tumor suppression in lymphoma model | |
| CN114949105B (en) | Medicinal toothpaste for preventing and treating oral mucositis caused by radiotherapy and chemotherapy | |
| WO2022235050A1 (en) | Composition for inhibiting tumor growth, containing extract of sanguisorba officinalis as active ingredient | |
| KR102144264B1 (en) | Composition for preventing and treating a cancer comprising leonurus sibiricus | |
| CN102440987A (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |